Biotron Limited (ASX:BIT)

ALERT: Price-sensitive ASX Announcement for BIT

Current share price for BIT : $0.002 -0.001 (-33.33%)⁺

Announcement

Quarterly Activities/Appendix 4C Cash Flow Report

Release

29 Apr 2026 10:01AM

Price at Release

$0.003

Full Release

Summary

Biotron Limited's quarterly activities report for the period ending 31 March 2026 outlines the company's financial and operational activities. Key achievements include the completion of Sedarex Limited's integration, progression of regulatory submissions for SedRx, and developments in anti-Hepatitis B and Delta Virus research. The company successfully raised additional funds through a rights issue and appointed a new Non-Executive Director. The report highlights expenditures on R&D and administrative costs, as well as cash flow details, indicating a net decrease in cash from operating activities. The company closed the quarter with cash and equivalents totaling $1.776 million.

Key Points

Completed integration of Sedarex Limited into Biotron.
Progressed submission for European Medicines Agency for SedRx.
Demonstrated BIT-HBV001's activity against Hepatitis Delta Virus.
Raised $878,733 from rights issue shortfall.
Appointed Dr Graeme Wald as Non-Executive Director.
Reported expenditures of $128,000 on R&D and $142,000 on staff costs.
Net cash used in operating activities was $686,000.
Cash and cash equivalents at end of quarter were $1.776 million.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.